Takeda Pharmaceutical Company Limited

Timothy Mark Turner

Albert Charles Gyorkos

Masakuni Kori

Christopher Peter Corrette

Kazuyoshi Aso

Suk Young Cho

Steven Armen Boyd

Kevin Ronald Condroski

Michiyo Mochizuki

Scott Alan Pratt

Christopher Stephen Siedem

Michiyo Gyoten

There is provided a CRF receptor antagonist comprising a compound of the formula (I):A-W&#x2014;Ar&#x2003;&#x2003;(I) 

Cyclic compounds

There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A'): wherein X is a carbon and Xis an oxygen, a sulfur or &#x2014;NR&#x2014;, or formula (A&#x2033;): wherein X is a nitrogen and Ris an optionally substituted hydrocarbyl, Ris an amino substituted by two optionally substituted hydrocarbyl groups, Ris an phenyl, Yis CRor a nitrogen, Yis CRor a nitrogen and Yis CRor a nitrogen, provided that one or less of Y, Y, and Yis nitrogen, W is a bond, &#x2014;(CH)n-, and Z is a bond, &#x2014;NR&#x2014;, etc.; or a salt thereof or a prodrug thereof.

Nitrogen-containing fused heterocyclic compounds

Growing community of inventors

Boulder, CO, United States of America

Timothy Mark Turner